ADQ Acquires Acino from Avista Capital and Nordic Capital

Acino Acquires Select IlmixGroup Pharmaceutical Portfolio in Russia

April 1, 2021

Pharmaceuticals

Acino has completed the acquisition of a select portfolio of prescription pharmaceutical products and food supplements from the IlmixGroup group of companies in Russia. The deal (asset purchase) includes multiple brands used in gynaecology, oncology, urology and dermatology and is accompanied by manufacturing and supply agreements with MiraxBioPharma to ensure continued local production.

Acino Acquires M8 Pharmaceuticals

September 20, 2023

Pharmaceuticals

Swiss pharmaceutical company Acino has agreed to acquire M8 Pharmaceuticals, a Mexico City–headquartered specialty biopharmaceutical company and Montreux Growth Partners portfolio company. The deal brings over 300 M8 employees, an established product portfolio and pipeline, and market access in Mexico and Brazil to expand Acino's footprint and capabilities across Latin America; the transaction is expected to close by the end of 2023 subject to customary approvals.

Cambrex Acquires Avista Pharma Solutions

January 2, 2019

Pharmaceuticals

Cambrex Corporation completed the acquisition of Avista Pharma Solutions from Ampersand Capital Partners in a transaction announced November 20, 2018 and completed January 2019 (reported consideration about $252 million). The deal brings Avista’s early‑stage drug development, analytical/testing and finished dosage capabilities (sites in Longmont, CO; Durham, NC; Agawam, MA; and Edinburgh, UK) into Cambrex’s global CDMO network to expand capabilities and cross‑sell services.

Novo Integrated Sciences / Novo Healthnet Acquire Acenzia Inc.

June 29, 2021

Pharmaceuticals

Novo Integrated Sciences, through its wholly owned subsidiary Novo Healthnet Limited, completed the acquisition of Acenzia Inc., a Windsor, Ontario-based nutraceutical manufacturer and diagnostics developer. The all-share transaction closed on June 24, 2021 and is valued at $14,884,039; Novo said the purchase will give it direct control of development, manufacturing and distribution of wellness products and personalized diagnostics.

Adragos Pharma Acquires Baccinex

February 6, 2025

Pharmaceuticals

Adragos Pharma, a Munich-headquartered CDMO, has acquired Baccinex, a Swiss sterile fill-finish specialist based in Courroux, Jura. The acquisition adds a US FDA- and EU-GMP-certified 6,200 m² facility and over 110 sterile fill-finish experts to Adragos' global manufacturing network, enhancing its clinical and commercial sterile manufacturing capabilities.

Ingenio Acquires adviqo Group to Create Global Wellness Media Leader

May 2, 2022

Media & Entertainment

Ingenio, a San Francisco-based portfolio company of Alpine Investors, has acquired Berlin-based adviqo Group, combining North American and European leaders in online spiritual and emotional wellness marketplaces and media. The deal creates a global leader in personal guidance and astrology media, expands geographic reach and product offerings, and leverages scale across their combined brands and audiences.